NY-IFF
1.2.2021 12:52:11 CET | Business Wire | Press release
IFF (NYSE: IFF) today launched a bold new brand identity designed to propel the Company’s transformation and reinforce its leadership role in the global value chain for consumer goods and commercial products. Upon the completion of its combination with DuPont’s Nutrition & Biosciences (N&B) business, IFF will begin a new era guided by an authentic customer-centric approach and commitment to execution, deep R&D and innovation capabilities, a storied legacy of artistry and a passion to be an essential partner for its customers around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005398/en/
As part of the new brand identity, IFF has launched a new tagline, purpose, brand commitments, and cultural attributes and values. The Company believes that these brand components will support the success of the four divisions that now comprise the new IFF.
IFF’s new brand identity and tagline : Where science and creativity meet , captures the company’s longstanding focus on the dynamic interplay between artistry and science to deliver differentiated, integrated solutions to customers that amaze and delight. IFF is a force for good in its communities worldwide, accelerating sustainability-driven change across its industry.
The company’s purpose , Applying science and creativity for a better world , continues to inspire everyone at IFF to push past traditional industry boundaries and commits to be a force for a better and more sustainable future.
Core to the company’s strategy for success, a central vision: Be the partner for essential solutions , reflects its vital leadership role in the global value chain for consumer goods and commercial products, and deep commitment to be guided by a customer-centric approach in everything we do.
The IFF brand continues to be underpinned by three commitments , adapted to better reflect the new organization.
- Question Everything : We’re here to shake things up and forge a new path. We’re working at the cutting edge of artistry and science and encourage new discoveries at every opportunity.
- Champion Creators : We believe our differences make us great. We power companies of every shape, size and style with the ingredients, solutions and passion to convert ideas into impact.
- Do More Good : Claiming perfection doesn’t help. We’re on a journey to do better for people and planet. Every day we bring the talent, influence and responsibility to constantly challenge the status quo.
“Today we start a transformative journey together to become a center of innovation for our customers,” said Andreas Fibig, IFF Chairman and Chief Executive Officer. “Our leadership team believes passionately in the importance and benefit of being a purpose-driven enterprise. We will lead not simply by relying on an unmatched portfolio and flawless execution, but by quickly unlocking new innovations as we tap into our shared passion for pairing science and creativity to deliver for our customers. We are creating an agile, empowered and innovative business that provides exceptional service and delivers on our commitment to be an essential partner for our customers.”
Mr. Fibig continued, “Critical to our success is our ability to foster an execution culture and embed values that support our promises to our people, customers, consumers and our communities. To that end, we have updated our cultural principles to ensure we have the foundation in place to empower our people to deliver on our commitments.”
IFF’s merger with N&B prompted the Company to establish a new set of core values and cultural principles as the foundation of its growth strategy. This resulted in the following cultural principles :
- ACT AS AN OWNER: We take ownership and work with passion and integrity. Our teams are empowered to make decisions and help the entire organization thrive.
- BE AGILE: We constantly push for progress and respond to the needs of our customers and the world with speed, skill, and creativity.
- COLLABORATE AND WIN TOGETHER: Our bond with our customers and colleagues powers innovation and our shared success.
IFF’s culture is further buoyed by its values:
- Empowerment: We make informed decisions, take action and have the courage to hold ourselves accountable for the outcomes.
- Expertise: We collaborate, applying our collective skills and diverse backgrounds to solve problems and achieve higher levels of performance.
- Integrity: We are inclusive, treat each other with respect and work in a fair, honest and ethical way.
- Innovation: We harness our creativity to deliver essential solutions for our partners and the communities we serve.
- Responsibility: We protect the health and safety of our people and preserve the communities where we work.
Introducing IFF’s Business Divisions
Nourish
The Company announced its combined Taste, Food & Beverage division will now be called Nourish.
To nourish is to feed with purpose
, a vision that guides IFF’s partnership with all stakeholders. Nourish, IFF’s largest division, is composed of IFF’s Taste division and N&B’s Food & Beverage segment. The new identity for Nourish better aligns the division with the enhanced capabilities, vision and purpose of the combined company as Nourish boldly imagines to create the future of food and beverage experiences.
Scent
IFF’s Scent division creates and pioneers unique fragrances, scent solutions and cosmetic actives across key consumer goods industries such as fine perfumery, personal, fabric and home care. Key enablers to these pioneering scents are unique fragrance ingredients and naturals which bring breakthrough olfactive innovation and augmented perfumery benefits. Scent leads fragrance artistry, scientific discovery and therapeutic breakthroughs that change the word for better by awakening human nature.
Health & Biosciences
Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Bioscience (H&B) platform is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. H&B works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions.
Pharma Solutions
IFF’s Pharma Solutions division is a trusted leader in developing the ingredients, products and applications that support global production of pharma and dietary supplements. With recognized brands and unmatched expertise, Pharma Solutions is setting new standards in a highly regulated industry.
To view IFF’s new brand video, visit this link . For more information about IFF’s new era at the intersection of science and creativity, visit iff.com .
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and sensorial experiences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005398/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
